07 May 2025
07 May 2025
Sarepta鈥檚 stock dropped by 26% after the FDA named a vocal critic of its gene therapy programme to lead its biologics division.
Shares in Novo Nordisk were still up after Q1 2025 witnessed a total revenue jump by 18%, compared to Q1 2024.
The deal builds on an existing research collaboration between Eli Lilly and Alchemab to discover new ALS drugs.
The options are for the freeze-dried version of Bavarian Nordic鈥檚 Jynneos, a formulation that allows easier stockpiling.
Recursion is streamlining its portfolio in the wake of its 2024 merger with鈥疎xscientia.
A panel at Swiss Biotech Day 2025 discussed three global parallel drug approval pathways.
The EC鈥檚 decision was supported by outcomes from the ECHO Phase III trial.
Global pharmaceutical stocks have declined following Trump's commitment to implement pharmaceutical tariffs.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
